Initial antimicrobial management of sepsis

Michael S Niederman, Rebecca M Baron, Lila Bouadma, Thierry Calandra, Nick Daneman, Jan DeWaele, Marin H Kollef, Jeffrey Lipman, Girish B Nair, Michael S Niederman, Rebecca M Baron, Lila Bouadma, Thierry Calandra, Nick Daneman, Jan DeWaele, Marin H Kollef, Jeffrey Lipman, Girish B Nair

Abstract

Sepsis is a common consequence of infection, associated with a mortality rate > 25%. Although community-acquired sepsis is more common, hospital-acquired infection is more lethal. The most common site of infection is the lung, followed by abdominal infection, catheter-associated blood steam infection and urinary tract infection. Gram-negative sepsis is more common than gram-positive infection, but sepsis can also be due to fungal and viral pathogens. To reduce mortality, it is necessary to give immediate, empiric, broad-spectrum therapy to those with severe sepsis and/or shock, but this approach can drive antimicrobial overuse and resistance and should be accompanied by a commitment to de-escalation and antimicrobial stewardship. Biomarkers such a procalcitonin can provide decision support for antibiotic use, and may identify patients with a low likelihood of infection, and in some settings, can guide duration of antibiotic therapy. Sepsis can involve drug-resistant pathogens, and this often necessitates consideration of newer antimicrobial agents.

Keywords: Antibiotic therapy; Antimicrobial therapy; Bacteremia; Biomarkers; Fungal infection; Intra-abdominal infection; Pharmacokinetics; Pneumonia; Sepsis.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
The need for immediate broad-spectrum empiric antimicrobial therapy for selected patients with severe sepsis may be life-saving, but may also put pressure to overuse antibiotics and drive antibiotic resistance. Thus, this approach comes with the obligation to try to control resistance by de-escalating therapy once serial clinical, microbiologic and laboratory data become available. De-escalation can be in the form of shorter duration of therapy, less broad-spectrum agents, fewer drugs, or a combination of these interventions
Fig. 2
Fig. 2
The rapidity of empiric therapy and the choice of specific agents are determined by the clinical scenario of the patient with suspected sepsis. Immediate therapy is given to those with a high likelihood of infection, and severe illness and or shock. If biomarkers like procalcitonin are not elevated, and the patient is not severely ill, immediate therapy is not necessary, and some patients may not even have infection. Specific agents are chosen with a consideration of the most common site of infection (lung > abdomen > catheter-associated infection > urinary tract infection). Each site has a group of likely pathogens, but these can vary, depending on patient-specific risk factors for resistance, and local ICU patterns of drug-resistant organisms. In sepsis, gram-negatives are more common than gram-positive, but some patients may also have fungal infection

References

    1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552. doi: 10.1097/CCM.0000000000002255.
    1. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3) JAMA. 2016;315(8):762–774. doi: 10.1001/jama.2016.0288.
    1. Reinhart K, Daniels R, Kissoon N, Machado FR, Schachter RD, Finfer S. recognizing sepsis as a global health priority—a WHO resolution. N Engl J Med. 2017;377(5):414–417. doi: 10.1056/NEJMp1707170.
    1. Fay K, Sapiano MRP, Gokhale R, Dantes R, Thompson N, Katz DE, et al. Assessment of health care exposures and outcomes in adult patients with sepsis and septic shock. JAMA Netw Open 2020;3(7):e206004.
    1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377. doi: 10.1007/s00134-017-4683-6.
    1. Martinez ML, Ferrer R, Torrents E, Guillamat-Prats R, Goma G, Suarez D, et al. Impact of source control in patients with severe sepsis and septic shock. Crit Care Med. 2017;45(1):11–19. doi: 10.1097/CCM.0000000000002011.
    1. @CDCgov. Clinical Information | Sepsis | CDC. 2021.
    1. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193(3):259–72.
    1. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–211. doi: 10.1016/S0140-6736(19)32989-7.
    1. Buchman TG, Simpson SQ, Sciarretta KL, Finne KP, Sowers N, Collier M, et al. Sepsis among medicare beneficiaries: 1. The burdens of sepsis, 2012–2018. Crit Care Med. 2020;48(3):276–88.
    1. Llewelyn MJ, Cohen J. Tracking the microbes in sepsis: advancements in treatment bring challenges for microbial epidemiology. Clin Infect Dis. 2007;44(10):1343–1348. doi: 10.1086/515403.
    1. Kern WV, Rieg S. Burden of bacterial bloodstream infection—a brief update on epidemiology and significance of multidrug-resistant pathogens. Clin Microbiol Infect. 2020;26(2):151–157. doi: 10.1016/j.cmi.2019.10.031.
    1. Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323(15):1478–1487. doi: 10.1001/jama.2020.2717.
    1. Rhee C, Wang R, Zhang Z, Fram D, Kadri SS, Klompas M, et al. Epidemiology of hospital-onset versus community-onset Sepsis in U.S. hospitals and association with mortality: a retrospective analysis using electronic clinical data. Crit Care Med. 2019;47(9):1169–76.
    1. Markwart R, Saito H, Harder T, Tomczyk S, Cassini A, Fleischmann-Struzek C, et al. Epidemiology and burden of sepsis acquired in hospitals and intensive care units: a systematic review and meta-analysis. Intensive Care Med. 2020;46(8):1536–1551. doi: 10.1007/s00134-020-06106-2.
    1. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136(5):1237–1248. doi: 10.1378/chest.09-0087.
    1. Zhang D, Micek ST, Kollef MH. Time to appropriate antibiotic therapy is an independent determinant of postinfection ICU and hospital lengths of stay in patients with sepsis. Crit Care Med. 2015;43(10):2133–2140. doi: 10.1097/CCM.0000000000001140.
    1. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118(1):146–155. doi: 10.1378/chest.118.1.146.
    1. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54(11):4851–4863. doi: 10.1128/AAC.00627-10.
    1. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462–474. doi: 10.1378/chest.115.2.462.
    1. Bassetti M, Rello J, Blasi F, Goossens H, Sotgiu G, Tavoschi L, et al. Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. Int J Antimicrob Agents. 2020;56(6):106184.
    1. Garnacho-Montero J, Diaz-Martin A, Canton-Bulnes L, Ramirez P, Sierra R, Arias-Verdu D, et al. Initial antifungal strategy reduces mortality in critically Ill patients with candidemia: a propensity score-adjusted analysis of a multicenter study. Crit Care Med. 2018;46(3):384–393. doi: 10.1097/CCM.0000000000002867.
    1. Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, De Pascale G, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med. 2014;40(6):839–845. doi: 10.1007/s00134-014-3310-z.
    1. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54(12):1739–1746. doi: 10.1093/cid/cis305.
    1. Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis. 2021;21(2):241–251. doi: 10.1016/S1473-3099(20)30477-1.
    1. Vazquez-Guillamet C, Scolari M, Zilberberg MD, Shorr AF, Micek ST, Kollef M. Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock. Crit Care Med. 2014;42(11):2342–2349. doi: 10.1097/CCM.0000000000000516.
    1. Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320(10):984–994. doi: 10.1001/jama.2018.12163.
    1. Taylor SP, Anderson WE, Beam K, Taylor B, Ellerman J, Kowalkowski MA. The association between antibiotic delay intervals and hospital mortality among patients treated in the emergency department for suspected sepsis. Crit Care Med. 2021;49(5):741–747. doi: 10.1097/CCM.0000000000004863.
    1. Weinberger J, Rhee C, Klompas M. A critical analysis of the literature on time-to-antibiotics in suspected sepsis. J Infect Dis. 2020;222(Suppl 2):S110–S118. doi: 10.1093/infdis/jiaa146.
    1. Rhee C, Kadri SS, Dekker JP, Danner RL, Chen HC, Fram D, et al. Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use. JAMA Netw Open. 2020;3(4):e202899.
    1. Asner SA, Desgranges F, Schrijver IT, Calandra T. Impact of the timeliness of antibiotic therapy on the outcome of patients with sepsis and septic shock. J Infect. 2021;82(5):125–134. doi: 10.1016/j.jinf.2021.03.003.
    1. Teshome BF, Vouri SM, Hampton N, Kollef MH, Micek ST. Duration of exposure to antipseudomonal beta-lactam antibiotics in the critically Ill and development of new resistance. Pharmacotherapy. 2019;39(3):261–270. doi: 10.1002/phar.2201.
    1. Teshome BF, Vouri SM, Hampton NB, Kollef MH, Micek ST. Evaluation of a ceiling effect on the association of new resistance development to antipseudomonal beta-lactam exposure in the critically ill. Infect Control Hosp Epidemiol. 2020;41(4):484–485. doi: 10.1017/ice.2019.381.
    1. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
    1. Pierrakos C, Velissaris D, Bisdorff M, Marshall JC, Vincent JL. Biomarkers of sepsis: time for a reappraisal. Crit Care. 2020;24(1):287. doi: 10.1186/s13054-020-02993-5.
    1. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463–474. doi: 10.1016/S0140-6736(09)61879-1.
    1. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care. 2007;11(2):R38. doi: 10.1186/cc5723.
    1. Skibsted S, Bhasin MK, Aird WC, Shapiro NI. Bench-to-bedside review: future novel diagnostics for sepsis—a systems biology approach. Crit Care. 2013;17(5):231. doi: 10.1186/cc12693.
    1. Miller RR, 3rd, Lopansri BK, Burke JP, Levy M, Opal S, Rothman RE, et al. Validation of a host response assay, SeptiCyte LAB, for discriminating sepsis from systemic inflammatory response syndrome in the ICU. Am J Respir Crit Care Med. 2018;198(7):903–913. doi: 10.1164/rccm.201712-2472OC.
    1. Wirz Y, Meier MA, Bouadma L, Luyt CE, Wolff M, Chastre J, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care. 2018;22(1):191. doi: 10.1186/s13054-018-2125-7.
    1. Arulkumaran N, Routledge M, Schlebusch S, Lipman J, Conway MA. Antimicrobial-associated harm in critical care: a narrative review. Intensive Care Med. 2020;46(2):225–235. doi: 10.1007/s00134-020-05929-3.
    1. De Backer D, Cecconi M, Lipman J, Machado F, Myatra SN, Ostermann M, et al. Challenges in the management of septic shock: a narrative review. Intensive Care Med. 2019;45(4):420–433. doi: 10.1007/s00134-019-05544-x.
    1. Roberts JA, Taccone FS, Lipman J. Understanding PK/PD. Intensive Care Med. 2016;42(11):1797–1800. doi: 10.1007/s00134-015-4032-6.
    1. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004;328(7441):668. doi: 10.1136/bmj.38028.520995.63.
    1. Marcus R, Paul M, Elphick H, Leibovici L. Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents. 2011;37(6):491–503. doi: 10.1016/j.ijantimicag.2010.11.029.
    1. Blot S, Lipman J, Roberts DM, Roberts JA. The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary? Diagn Microbiol Infect Dis. 2014;79(1):77–84. doi: 10.1016/j.diagmicrobio.2014.01.015.
    1. Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic resistance–what's dosing got to do with it? Crit Care Med. 2008;36(8):2433–2440. doi: 10.1097/CCM.0b013e318180fe62.
    1. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al. A multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med. 2015;192(11):1298–1305. doi: 10.1164/rccm.201505-0857OC.
    1. Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient–concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11. doi: 10.1016/j.addr.2014.07.006.
    1. Udy AA, Baptista JP, Lim NL, Joynt GM, Jarrett P, Wockner L, et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*. Crit Care Med. 2014;42(3):520–527. doi: 10.1097/CCM.0000000000000029.
    1. Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. Therapeutic drug monitoring of the beta-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother. 2015;70(12):3178–3183.
    1. Armand-Lefevre L, Ruppe E, Andremont A. ESBL-producing Enterobacteriaceae in travellers: doctors beware. Lancet Infect Dis. 2017;17(1):8–9. doi: 10.1016/S1473-3099(16)30417-0.
    1. Hites M. Minireview on novel anti-infectious treatment options and optimized drug regimens for sepsis. Front Med (Lausanne). 2021;8:640740.
    1. Butler MS, Paterson DL. Antibiotics in the clinical pipeline in October 2019. J Antibiot (Tokyo) 2020;73(6):329–364. doi: 10.1038/s41429-020-0291-8.
    1. Kakasis A, Panitsa G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. Int J Antimicrob Agents. 2019;53(1):16–21.
    1. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–67.
    1. Carugati M, Aliberti S, Sotgiu G, Blasi F, Gori A, Menendez R, et al. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. Eur J Clin Microbiol Infect Dis. 2020;39(8):1513–1525. doi: 10.1007/s10096-020-03870-3.
    1. Pletz MW, Blasi F, Chalmers JD, Dela Cruz CS, Feldman C, Luna CM, et al. International perspective on the new 2019 American Thoracic Society/infectious diseases society of america community-acquired pneumonia guideline: a critical appraisal by a global expert panel. Chest. 2020;158(5):1912–1918. doi: 10.1016/j.chest.2020.07.089.
    1. Nair GB, Niederman MS. Updates on community acquired pneumonia management in the ICU. Pharmacol Ther. 2021;217:107663.
    1. Vardakas KZ, Trigkidis KK, Falagas ME. Fluoroquinolones or macrolides in combination with beta-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2017;23(4):234–241. doi: 10.1016/j.cmi.2016.12.002.
    1. Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014;42(2):420–432. doi: 10.1097/CCM.0b013e3182a66b9b.
    1. Jones BE, Jones MM, Huttner B, Stoddard G, Brown KA, Stevens VW, et al. Trends in antibiotic use and nosocomial pathogens in hospitalized veterans with pneumonia at 128 medical centers, 2006–2010. Clin Infect Dis. 2015;61(9):1403–1410. doi: 10.1093/cid/civ629.
    1. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis. 2014;58(3):330–339. doi: 10.1093/cid/cit734.
    1. Attridge RT, Frei CR, Pugh MJ, Lawson KA, Ryan L, Anzueto A, et al. Health care-associated pneumonia in the intensive care unit: guideline-concordant antibiotics and outcomes. J Crit Care. 2016;36:265–271. doi: 10.1016/j.jcrc.2016.08.004.
    1. Minejima E, Lou M, Nieberg P, Wong-Beringer A. Patients presenting to the hospital with MRSA pneumonia: differentiating characteristics and outcomes with empiric treatment. BMC Infect Dis. 2014;14:252. doi: 10.1186/1471-2334-14-252.
    1. Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, et al. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis. 2016;16(12):1364–1376. doi: 10.1016/S1473-3099(16)30267-5.
    1. Jung WJ, Kang YA, Park MS, Park SC, Leem AY, Kim EY, et al. Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia. BMC Infect Dis. 2013;13:370. doi: 10.1186/1471-2334-13-370.
    1. Prina E, Ranzani OT, Polverino E, Cilloniz C, Ferrer M, Fernandez L, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015;12(2):153–160. doi: 10.1513/AnnalsATS.201407-305OC.
    1. von Baum H, Welte T, Marre R, Suttorp N, Ewig S, Group Cs. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur Respir J. 2010;35(3):598–605.
    1. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013;188(8):985–995. doi: 10.1164/rccm.201301-0079OC.
    1. Morel J, Casoetto J, Jospe R, Aubert G, Terrana R, Dumont A, et al. De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care. 2010;14(6):R225.
    1. Leone M, Bechis C, Baumstarck K, Lefrant JY, Albanese J, Jaber S, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med. 2014;40(10):1399–1408. doi: 10.1007/s00134-014-3411-8.
    1. Buckel WR, Stenehjem E, Sorensen J, Dean N, Webb B. Broad- versus narrow-spectrum oral antibiotic transition and outcomes in health care-associated pneumonia. Ann Am Thorac Soc. 2017;14(2):200–205.
    1. Deshpande A, Richter SS, Haessler S, Lindenauer PK, Yu PC, Zilberberg MD, et al. De-escalation of empiric antibiotics following negative cultures in hospitalized patients with pneumonia: rates and outcomes. Clin Infect Dis. 2021;72(8):1314–1322. doi: 10.1093/cid/ciaa212.
    1. Kato H, Hagihara M, Asai N, Shibata Y, Koizumi Y, Yamagishi Y, et al. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist. 2021;24:98–105. doi: 10.1016/j.jgar.2020.12.009.
    1. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111. doi: 10.1093/cid/ciw353.
    1. Luna CM, Aruj P, Niederman MS, Garzon J, Violi D, Prignoni A, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J. 2006;27(1):158–164. doi: 10.1183/09031936.06.00049105.
    1. Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008;23(1):91–100. doi: 10.1016/j.jcrc.2007.08.007.
    1. Muscedere JG, Shorr AF, Jiang X, Day A, Heyland DK, Canadian Critical Care Trials G. The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome. J Crit Care. 2012;27(3):322 e7–14.
    1. Martin-Loeches I, Timsit JF, Leone M, de Waele J, Sartelli M, Kerrigan S, et al. Clinical controversies in abdominal sepsis. Insights for critical care settings. J Crit Care. 2019;53:53–8.
    1. Blot S, Antonelli M, Arvaniti K, Blot K, Creagh-Brown B, de Lange D, et al. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: "AbSeS", a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Med. 2019;45(12):1703–1717. doi: 10.1007/s00134-019-05819-3.
    1. Martin-Loeches I, Antonelli M, Cuenca-Estrella M, Dimopoulos G, Einav S, De Waele JJ, et al. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019;45(6):789–805. doi: 10.1007/s00134-019-05599-w.
    1. Phua J, Ngerng W, See K, Tay C, Kiong T, Lim H, et al. Characteristics and outcomes of culture-negative versus culture-positive severe sepsis. Crit Care. 2013;17(5):R202. doi: 10.1186/cc12896.
    1. Gupta S, Sakhuja A, Kumar G, McGrath E, Nanchal RS, Kashani KB. Culture-negative severe sepsis: nationwide trends and outcomes. Chest. 2016;150(6):1251–1259. doi: 10.1016/j.chest.2016.08.1460.
    1. MacFadden DR, Leis JA, Mubareka S, Daneman N. The opening and closing of empiric windows: the impact of rapid microbiologic diagnostics. Clin Infect Dis. 2014;59(8):1199–1200. doi: 10.1093/cid/ciu493.
    1. Randhawa V, Sarwar S, Walker S, Elligsen M, Palmay L, Daneman N. Weighted-incidence syndromic combination antibiograms to guide empiric treatment of critical care infections: a retrospective cohort study. Crit Care. 2014;18(3):R112. doi: 10.1186/cc13901.
    1. Hebert C, Ridgway J, Vekhter B, Brown EC, Weber SG, Robicsek A. Demonstration of the weighted-incidence syndromic combination antibiogram: an empiric prescribing decision aid. Infect Control Hosp Epidemiol. 2012;33(4):381–388. doi: 10.1086/664768.
    1. Cressman AM, MacFadden DR, Verma AA, Razak F, Daneman N. Empiric antibiotic treatment thresholds for serious bacterial infections: a scenario-based survey study. Clin Infect Dis. 2019;69(6):930–937. doi: 10.1093/cid/ciy1031.
    1. MacFadden DR, Coburn B, Shah N, Robicsek A, Savage R, Elligsen M, et al. Decision-support models for empiric antibiotic selection in Gram-negative bloodstream infections. Clin Microbiol Infect. 2019;25(1):108 e1–7.
    1. Elligsen M, Pinto R, Leis JA, Walker SAN, Daneman N, MacFadden DR. Improving decision-making in empiric antibiotic selection (IDEAS) for gram-negative bacteremia: a prospective clinical implementation study. Clin Infect Dis. 2020.
    1. MacFadden DR, Coburn B, Shah N, Robicsek A, Savage R, Elligsen M, et al. Utility of prior cultures in predicting antibiotic resistance of bloodstream infections due to Gram-negative pathogens: a multicentre observational cohort study. Clin Microbiol Infect. 2018;24(5):493–499. doi: 10.1016/j.cmi.2017.07.032.
    1. Elligsen M, Pinto R, Leis JA, Walker SAN, MacFadden DR, Daneman N. Using prior culture results to improve initial empiric antibiotic prescribing: an evaluation of a simple clinical heuristic. Clin Infect Dis. 2021;72(10):e630–e638. doi: 10.1093/cid/ciaa1397.
    1. MacFadden DR, Elligsen M, Robicsek A, Ricciuto DR, Daneman N. Utility of prior screening for methicillin-resistant Staphylococcus aureus in predicting resistance of S. aureus infections. CMAJ. 2013;185(15):E725–30.
    1. Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence. 2014;5(1):161–169. doi: 10.4161/viru.26187.
    1. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis. 2004;38(3):311–320. doi: 10.1086/380637.
    1. Pfaller MA, Carvalhaes CG, Smith CJ, Diekema DJ, Castanheira M. Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012–2017). Diagn Microbiol Infect Dis. 2020;97(2):115016.
    1. Bassetti M, Vena A, Meroi M, Cardozo C, Cuervo G, Giacobbe DR, et al. Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts. Crit Care. 2020;24(1):117. doi: 10.1186/s13054-020-2793-y.
    1. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026. doi: 10.1038/nrdp.2018.26.
    1. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med. 2009;35(9):1526–1531. doi: 10.1007/s00134-009-1482-8.
    1. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220(6):751–758. doi: 10.1097/00000658-199412000-00008.
    1. Charles PE, Doise JM, Quenot JP, Aube H, Dalle F, Chavanet P, et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med. 2003;29(12):2162–2169. doi: 10.1007/s00134-003-2002-x.
    1. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol. 2005;43(3):235–243. doi: 10.1080/13693780410001731619.
    1. Leon C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34(3):730–737. doi: 10.1097/01.CCM.0000202208.37364.7D.
    1. Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2011;54(1):46–51. doi: 10.1111/j.1439-0507.2009.01756.x.
    1. Clancy CJ, Nguyen MH. Diagnosing invasive candidiasis. J Clin Microbiol. 2018;56(5).
    1. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C, Third European Conference on Infections in Leukemia G. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14(6):R222.
    1. Lamoth F, Akan H, Andes D, Cruciani M, Marchetti O, Ostrosky-Zeichner L, et al. Assessment of the role of 1,3-beta-d-glucan testing for the diagnosis of invasive fungal infections in adults. Clin Infect Dis. 2021;72(Suppl 2):S102–S108. doi: 10.1093/cid/ciaa1943.
    1. Monday LM, Parraga Acosta T, Alangaden G. T2Candida for the diagnosis and management of invasive candida infections. J Fungi (Basel). 2021;7(3).
    1. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020–2029. doi: 10.1056/NEJMoa021585.
    1. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472–2482. doi: 10.1056/NEJMoa066906.
    1. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–50. doi: 10.1093/cid/civ933.
    1. Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect. 2019;25(7):792–798. doi: 10.1016/j.cmi.2019.03.028.
    1. Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 2020;16(10):e1008921. doi: 10.1371/journal.ppat.1008921.
    1. Patterson TF, Thompson GR, 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi: 10.1093/cid/ciw326.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다